Christine Lovly, MD, PhD

This segment dives into two of the most practically important questions facing clinicians who manage ALK-positive NSCLC: how to optimally test for ALK rearrangements, and how to select among the growing number of first-line treatment options available today.

This segment opens with foundational context on ALK-positive non-small cell lung cancer, establishing the clinical and scientific backdrop that makes this disease state — and its recent treatment advances — so compelling.